Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
Vanessa A Evans, Renee M van der Sluis, Ajantha Solomon, Ashanti Dantanarayana, Catriona McNeil, Roger Garsia, Sarah Palmer, Remi Fromentin, Nicolas Chomont, Rafick-Pierre Sekaly, Paul U Cameron, Sharon R Lewin
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Awarded by American Foundation for AIDS Research, amfAR
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by National Institutes of Health Delaney AIDS Research Enterprise (DARE)
Anti-PD-1 antibodies were kindly supplied by Merck (MK-3475/pembrolizumab; in-vitro studies) and Bristol Myers Squibb (nivolumab; supplied under their Special Access Scheme for the in-vivo study). This work was supported by funds from the American Foundation for AIDS Research, amfAR (grant numbers 108237-51-RGRL and 109226-58-RGRL); the National Health and Medical Research Council (NHMRC) of Australia (grant number APP1041795); and the National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure collaboratory (grant numbers U19 AI096109 and UM1AI126611). S.R.L. is an NHMRC Practitioner Fellow. The authors have no conflicting financial interests.